The in-silico evaluation and the in vivo experimentation results suggest that the favorable effects on those parameters are probably attributable to the interaction of 1b with several targets related to MetS, including PPAR receptors and enzymes like ACE and HMG-CoA reductase. This evidence concerns the gene HMGCR and metabolic syndrome.